You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Development of a Gene and Oligonucleotide Delivery System

    SBC: MOLECULAR EXPRESS, INC            Topic: NCATS

    DESCRIPTION provided by applicant The knockdown of targeted genes by anti sense oligonucleotides ODNS and genetic medicines collectively G MEDS holds promise for a variety of therapies The delivery of effective quantities of ODNS to specific cells however has proved to be challenging We propose here a novel approach to ODN delivery that involves enveloped virus like particles EVLPs ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Dysbiotic Rebalancing with S. epidermidis Fermentation in Acne Vulgaris

    SBC: Surface Bioadvances, Inc.            Topic: NIAMS

    DESCRIPTION provided by applicant Dysbiosis refers to a condition with microbial imbalances within the human microbiome Yogurts are the best examples of using fermenting gut bacteria to rebalance the gut dysbiosis Our results demonstrate for the first time that Staphylococcus epidermidis S epidermidis a commensal bacterium of the human skin functions as a probiotic microorganism that em ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Effectiveness of VBP15, a dissociative steroidal analogue, on inflammation in a mouse model of arthritis

    SBC: REVERAGEN BIOPHARMA, INC.            Topic: NIAMS

    DESCRIPTION provided by applicant Glucocorticoids GCandapos s such as prednisolone are used frequently to induce remission and treat rheumatoid arthritis RA Despite effectiveness many GC mediated detrimental side effects including osteoporosis and muscle atrophy limit long term chronic treatment of RA patients In addition juvenile arthritis patients suffer from th side effect of signi ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Therapeutic Antibodies for Biofilm Infections

    SBC: TRELLIS BIOSCIENCE, INC.            Topic: NIAID

    DESCRIPTION provided by applicant About of serious bacterial infections are biofilm mediated Not only do biofilms provide an anchor and physical protection for bacterial cells but the physiology and genetic programming of bacteria also shifts between the planktonic free floating and sessile stationary states Most notably antibiotic sensitivity differs betwen the two states with ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  5. Improving the therapeutic efficacy of a lead vaccine against plague using a novel adjuvant system

    SBC: FasCure Therapeutics LLC            Topic: NIAID

    DESCRIPTION provided by applicant FasCure Therapeutics focuses on the development of adjuvant systems to generate prophylactic and therapeutic immune responses The major objective of this Phase STTR proposal is to reformulate a lead plague subunit vaccine with a novel adjuvant system to improve its protective efficacy Yersinia pestis is the causative agent of bubonic and pneumonic plague ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Novel Activin A Antagonists for Treatment of Osteoporosis

    SBC: ABREOS BIOSCIENCES, INC.            Topic: NIAMS

    DESCRIPTION provided by applicant Bone loss and fragility from osteoporosis afflict more than million people worldwide including at least million Americans Current osteoporosis treatments are significantly deficient most fail to reverse bone loss and or have adverse effects that prohibit their long term use New therapeutic approaches are urgently needed Recently the TGF family li ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  7. Maximal MYC control using dual PI-3K/BRD4 (kinase/epigenetic) inhibitors

    SBC: SignalRx Pharmaceuticals Inc.            Topic: 102

    DESCRIPTION provided by applicant There is an unmet need to inhibit the key cancer promoting transcription factor MYC MYC both cMYC and MYCN acts downstream of many cell receptor complexes and signal transduction pathways to activate genes that drive cancer cell growth and proliferation To date small molecule inhibitors of MYC have been elusive An innovative approach would be to indirectl ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Retargeting FDA Approved Anticancer Liposomal Drugs to Cancer Stem Cells

    SBC: ZoneOne Pharma            Topic: O

    DESCRIPTION provided by applicant The goal of this research is to develop a ligand product and facile method to use it to target FDA approved liposomal anticancer drugs to cancer stem cells that overexpress CD We have devised a highly efficient chemo enzymatic synthesis of a hyaluronan lipid HA lipid ligand and have teamed with ZoneOne Pharma to develop a simple and robust micelle transfer ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. A dual-polarized Doppler Radar system for fall detection in an indoor environment

    SBC: MS Technologies Corporation            Topic: NIA

    DESCRIPTION provided by applicant Falls are a leading cause of injuries and deaths among older adults OAs and will be an increasing public health concern given projections of future increases in the number of OAs in the US Fall detection and or surveillance systems are needed to enhance an OAandapos s confidence and independence and to facilitate rapid post fall responses This project wil ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Development of Therapeutics to Treat Candida albicans Biofilm Infections

    SBC: BIOSYNESIS, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The yeast Candida albicans is a normal resident of the human digestive tract It is also the most common fungal pathogen of humans causing both mucosal and systemic infections particularly in immune compromised individuals The majority of new C albicans infections arise from the presence of persistent C albicans cells existing in a biofilm These biofilm b ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government